Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suguru Shirotake

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Medical Oncology (Northwood, London, England)|October 25, 2017
Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapyKyohei Hakozaki, Eiji Kikuchi, Keishiro Fukumoto, et al.
IJU Case Reports|August 4, 2020
A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis-assisted transurethral resection involving orally administered 5-aminolevulinic acidKeitaro Watanabe, Suguru Shirotake, Yuta Umezawa, et al.
BJUI Compass|February 19, 2024
New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinomaTakafumi Saito, Kent Kanao, Kazuhiro Matsumoto, et al.
International Journal of Clinical Oncology|July 24, 2024
Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumabTakayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.
International Journal of Clinical Oncology|June 8, 2021
On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinomaKimiharu Takamatsu, Ryuichi Mizuno, Yuto Baba, et al.
Anticancer Research|April 30, 2022
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell CarcinomaSuguru Shirotake, Y U Miyama, Yasutaka Baba, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
Japanese Journal of Clinical Oncology|March 11, 2016
Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomyHiroaki Kobayashi, Eiji Kikuchi, Nobuyuki Tanaka, et al.
International Journal of Clinical Oncology|September 2, 2023
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysisSatoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.
Japanese Journal of Clinical Oncology|September 7, 2020
Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancerKyohei Hakozaki, Eiji Kikuchi, Koichiro Ogihara, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Medical Oncology (Northwood, London, England)|October 25, 2017
Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapyKyohei Hakozaki, Eiji Kikuchi, Keishiro Fukumoto, et al.
IJU Case Reports|August 4, 2020
A case in which bladder cancer invaded the ureteral orifice and was resected via photodynamic diagnosis-assisted transurethral resection involving orally administered 5-aminolevulinic acidKeitaro Watanabe, Suguru Shirotake, Yuta Umezawa, et al.
BJUI Compass|February 19, 2024
New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinomaTakafumi Saito, Kent Kanao, Kazuhiro Matsumoto, et al.
International Journal of Clinical Oncology|July 24, 2024
Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumabTakayuki Nakayama, Hideki Takeshita, Makoto Kagawa, et al.
International Journal of Clinical Oncology|June 8, 2021
On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinomaKimiharu Takamatsu, Ryuichi Mizuno, Yuto Baba, et al.
Anticancer Research|April 30, 2022
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell CarcinomaSuguru Shirotake, Y U Miyama, Yasutaka Baba, et al.
Japanese Journal of Clinical Oncology|May 8, 2019
Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapyGo Kaneko, Suguru Shirotake, Koshiro Nishimoto, et al.
Japanese Journal of Clinical Oncology|March 11, 2016
Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomyHiroaki Kobayashi, Eiji Kikuchi, Nobuyuki Tanaka, et al.
International Journal of Clinical Oncology|September 2, 2023
Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysisSatoshi Washino, Suguru Shirotake, Hideki Takeshita, et al.
Japanese Journal of Clinical Oncology|September 7, 2020
Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancerKyohei Hakozaki, Eiji Kikuchi, Koichiro Ogihara, et al.
Pageof 9